Koparin

Koparin

SCHEMBL5723673

COc1ccc(-c2coc3cc(O)ccc3c2=O)c(O)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 1.00
HSD17B10 Q99714 10/20 1.00
ALDH1A1 P00352 10/20 1.00
HPGD P15428 9/20 1.00
MAPT P10636 5/20 1.00
TDP1 Q9NUW8 2/20 1.00
ALOX15 P16050 1/20 1.00
RECQL P46063 1/20 1.00
SMN1; SMN2 Q16637 5/20 0.73
CYP3A4 P08684 4/20 0.73
USP2 O75604 2/20 0.73
GLA P06280 1/20 0.73
NPC1 O15118 5/20 0.70
RAB9A P51151 5/20 0.70
TP53 P04637 3/20 0.70
MAPK1 P28482 1/20 0.70
POLB P06746 2/20 0.68
HMGB1 P09429 1/20 0.68
PPARG P37231 3/20 0.62
PPARD Q03181 3/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Koparin SCHEMBL29477154 1.00 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDMAPT
Khrinone E SCHEMBL31352025 0.90 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDMAPT
Khrinone E SCHEMBL21168203 0.90 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDMAPT
SCHEMBL27916248 0.89 KDM4E (0.80) KDM4EHSD17B10ALDH1A1HPGDMAPT
SCHEMBL13669867 0.88 KDM4E (0.85) KDM4EHSD17B10ALDH1A1HPGDMAPT
SCHEMBL234467 0.84 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDMAPT
SCHEMBL17938790 0.84 KDM4E (0.76) KDM4EHSD17B10ALDH1A1HPGDMAPT
SCHEMBL30991585 0.84 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDMAPT
2'-Methoxyformonetin SCHEMBL29777010 0.84 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDMAPT
2'-Methoxyformonetin SCHEMBL234355 0.84 KDM4E (1.00) KDM4EHSD17B10ALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118948925-A A composition extracted from Celastrus orbiculatus plant for treating cancer, and its preparation method and application 广西仙手棋药业科技有限公司 2024-11-15 CN claimed
CN-117959276-A A composition extracted from Celastrus orbiculatus plant for treating cancer, and its preparation method and application 广西仙手棋药业科技有限公司 2024-05-03 CN claimed
CN-118948925-A A composition extracted from Celastrus orbiculatus plant for treating cancer, and its preparation method and application 广西仙手棋药业科技有限公司 2024-11-15 CN disclosed
CN-117959276-A A composition extracted from Celastrus orbiculatus plant for treating cancer, and its preparation method and application 广西仙手棋药业科技有限公司 2024-05-03 CN disclosed
US-20220125766-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION MAGGIES PEARL LLC (US) 2022-04-28 US disclosed
US-11160794-B2 Methods for treating congenital disorders of glycosylation MAGGIE'S PEARL, LLC (US) 2021-11-02 US disclosed
US-20210030721-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION PERLARA PBC 2021-02-04 US disclosed
WO-2020040831-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION PERLARA PBC (US) 2020-02-27 WO disclosed
US-9527878-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-12-27 US disclosed
US-9527878-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-12-27 US disclosed
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-01-14 US disclosed
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-01-14 US disclosed
US-20150272939-A1 Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase YALE UNIVERSITY (US) 2015-10-01 US disclosed
US-20150272939-A1 Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase YALE UNIVERSITY (US) 2015-10-01 US disclosed
US-9120744-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-09-01 US disclosed
US-20140275224-A1 CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2014-09-18 US disclosed
US-20140275224-A1 CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2014-09-18 US disclosed
WO-2013074059-A2 CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2013-05-23 WO disclosed
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2010-06-03 US disclosed
EP-0771794-B1 OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO KK (JP) 2006-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism SERPINE1, PLAT, SERPINB1 KDM4E 3907/4885HSD17B10 275/4885ALDH1A1 918/4885
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM SERPINE1, PLAT, SERPINB1 KDM4E 3907/4885HSD17B10 275/4885ALDH1A1 918/4885
US-11160794-B2 Methods for treating congenital disorders of glycosylation MAN1B1, MAN2B1, GAA KDM4E 3915/4885HSD17B10 487/4885ALDH1A1 1692/4885
US-20210030721-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION MAN1B1, MAN2B1, GAA KDM4E 3915/4885HSD17B10 487/4885ALDH1A1 1692/4885
US-20140275224-A1 CYTOSINE DEAMINASE MODULATORS FOR ENHANCEMENT OF DNA TRANSFECTION CDA, DCTD, ADA KDM4E 1984/4885HSD17B10 2562/4885ALDH1A1 2191/4885
US-20220125766-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION MAN1B1, MAN2B1, GAA KDM4E 3915/4885HSD17B10 487/4885ALDH1A1 1692/4885
US-20150272939-A1 Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase KDM1B, KDM1A, JMJD1C KDM4E 19/4885HSD17B10 706/4885ALDH1A1 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.